Services on Demand
Journal
Article
Indicators
Cited by SciELO
Access statistics
Related links
Cited by Google
Similars in SciELO
Similars in Google
Share
Universitas Medica
Print version ISSN 0041-9095On-line version ISSN 2011-0839
Abstract
MARTINEZ BELTRAN, Leila; OZAETA EIDELMAN, Daniel and GONZALEZ SUAREZ, Natalia Lucía. Characterization of Children with Non-Metastatic Osteosarcoma who Received Treatment with Mifamurtide in Two Institutions in Colombia between 2014 and 2017. Univ. Med. [online]. 2019, vol.60, n.4, pp.23-30. ISSN 0041-9095. https://doi.org/10.11144/javeriana.umed60-4.oste.
Introducción:
Osteosarcoma is the most frequent bone tumor in children. Survival of patients who do not have metastases at the beginning has not changed in the last decade; there are studies that suggest the benefit of the use of new molecules such as mifamurtide.
Methods:
We described the variables of interest in 8 patients under 18 years of age with high-grade non-metastatic osteosarcoma, who received management with conventional chemotherapy and mifamurtide as adjuvant in 2 Colombian institutions between 2014 and 2017.
Results:
The majority of the patients had femoral compromise due to conventional osteosarcoma, all of them received management with pre and post-surgical chemotherapy, 75% of the patients were taken to limb salvage. In total, 375 cycles of mifamurtide were evaluated (2 mg/m2 of total body surface area). There were adverse effects in 7 of the 375 cycles administered (1.87 %); these occurred in 4 of the 8 patients participating in the study; at the end of the study, 6 of 8 patients were alive.
Conclusions:
In the patients evaluated, the use of mifamurtide was well tolerated, however due to the type of study it cannot be determined if the use of this medication had an impact on survival.
Keywords : osteosarcoma; mifamurtide; child; survival.